Plain language summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma Editorial
| Authors: | Rodriguez-Otero, P.; Ailawadhi, S.; Arnulf, B.; Patel, K.; Cavo, M.; Nooka, A. K.; Manier, S.; Callander, N.; Costa, L. J.; Vij, R.; Bahlis, N. J.; Moreau, P.; Solomon, S. R.; Delforge, M.; Berdeja, J.; Truppel-Hartmann, A.; Yang, Z.; Favre-Kontula, L.; Wu, F.; Piasecki, J.; Cook, M.; Giralt, S. |
| Title: | Plain language summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma |
| Abstract: | What is this summary about?: This plain language summary describes the results of a Phase 3 study called KarMMa-3. In this ongoing study, researchers looked at a relatively new treatment for people with multiple myeloma, a type of blood cancer, whose cancer got worse despite treatment (refractory) or had cancer that at first improved with treatment, but eventually stopped responding (relapsed). How was this study conducted?: In the KarMMa-3 study, people with relapsed or refractory multiple myeloma received either a one-time infusion of a new treatment, named ide-cel, or one of the standard of care regimens currently available for patients with this cancer. People were treated with the standard of care regimens in weekly or monthly cycles until the cancer got worse, there were unacceptable side effects, or the person withdrew from the study. What were the results?: The results of this study showed that people receiving the one-time infusion of ide-cel lived longer without the cancer getting worse and had a greater reduction in cancer cells than patients receiving the standard of care regimen. A higher percentage of patients receiving ide-cel responded to treatment than patients receiving the standard of care regimen, and the response to treatment was better with idecel. These results show that ide-cel is a promising treatment for this challenging disease. Clinical Trial Registration:NCT03651128 (KarMMa-3 study). © 2024 The Authors. |
| Keywords: | adult; treatment outcome; overall survival; fatigue; diarrhea; drug efficacy; drug safety; side effect; neurotoxicity; antineoplastic agent; t lymphocyte; progression free survival; proteasome inhibitor; multiple myeloma; neoplasm recurrence, local; anemia; leukopenia; vomiting; antineoplastic combined chemotherapy protocols; drug resistance; drug resistance, neoplasm; fever; lymphocytopenia; health care quality; immunotherapy; minimal residual disease; tumor burden; tumor recurrence; health care personnel; chimeric antigen receptor; drug therapy; oligopeptides; disease exacerbation; therapy; clinical trials; carfilzomib; hair loss; phase 3 clinical trial (topic); standard of care; leukapheresis; oligopeptide; cytokine release syndrome; hematologic; overall response rate; novel therapy; humans; human; male; female; article; b cell maturation antigen; daratumumab; clinical trial registration; plain language; idecabtagene vicleucel; relapsed or refractory multiple myeloma; hematologic/myeloma |
| Journal Title: | Future Oncology |
| Volume: | 20 |
| Issue: | 18 |
| ISSN: | 1479-6694 |
| Publisher: | Future Medicine |
| Date Published: | 2024-01-01 |
| Start Page: | 1221 |
| End Page: | 1235 |
| Language: | English |
| DOI: | 10.2217/fon-2023-0954 |
| PUBMED: | 38651976 |
| PROVIDER: | scopus |
| PMCID: | PMC11333973 |
| DOI/URL: | |
| Notes: | Source: Scopus |
